You are here

Agency Actions

Artificial Intelligence Enables Platform to Detect Amyloid PET Status
Inhaled Form of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
FDA Gives Priority Regulatory Review of Diagnostic for Fast-Progressing Kidney Disease
Rare, Life-threatening Disease Has No Approved Treatment
Superior to Quinine in Reducing Mortality in Two Clinical Trials
KardiaMobile Receives Two More Clearances for Arrhythmia Detection
May Offer Improved Safety Profile for Pediatric Patients
Possible First Treatment Option for Rare Autoimmune Disease of the CNS
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
First Patient Expected to Receive AMT-130 Therapy in 2019
Incurable Genetic Condition Affects One in 3-4,000 People
First-in-Human Phase 1 Trial Will Begin This Year
Aggressive T-cell Prolymphocytic Leukemia Has Very Limited Treatment Options
Subcutaneous Agent Could Prevent Laparoscopic Surgery, Emergency Surgery
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
MP-101 Has Potential to Drastically Alter Disease Progression
ACE-083 May Improve Strength in Target Muscles, Enhance Quality of Life
FDA, CDC, and CMS Team Up To Improve Disaster Response Planning
Drug Has Potential Role In Oxidative Stress, Inflammation, and Neurodegeneration
Intratumoral Injection Stimulates Immune Activation
Development of “Immune/Transduction Modulator” Gaining Momentum
Treatment for Adults With Symptomatic Tenosynovial Giant Cell Tumor
Biomechanical Vascular Closure Device Reduces Time to Hemostasis
First Investigational Gene Therapy for Monogenic Heart Failure Syndrome
Targeted Antibody for FGR3-Positive Mutation
Aggressive Disease Represents Around 6% of All New Cases of NHL